Ajanta Pharma advanced 3.18% to Rs 2,123.90 after the company said that its board will meet on Tuesday, 28 December 2021, to consider a proposal for buy-back of equity shares of the company.
The announcement was made after trading hours yesterday, 23 December 20221.
Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa.
The company's consolidated net profit rose 15.11% to Rs 195.94 crore on a 23.59% increase in sales to Rs 884.80 crore in Q2 FY22 over Q2 FY21.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
